PUBLIC COMPANY
saveZYDUS
USupdated 6mo ago
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(0)
no pipeline products on record
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- FDA Approves Once-Weekly Generic Hormone Therapy Patch for WomenToday, the U.S. Food and Drug Administration approved the first generic of Climara Pro (estradiol and levonorgestrel transdermal system, 0.045 mg per day/0.015 mg), a transdermal hormone therapy pa…fda_press · 7d ago
- Sentynl bets up to $475M in licensing deal for Mereo’s rare lung disease assetMereo BioPharma’s asset, dubbed alvelestat, is set to enter Phase 3 development for AATD-LD in 2027.biospace · 2mo ago
- Zydus’ Sentynl pens $475M deal for Mereo’s phase 3-ready rare genetic lung disease drugSentynl Therapeutics has penned a deal potentially worth $475 million for the option to market Mereo BioPharma's phase 3-ready rare genetic respiratory disease drug in the U.S.fiercebiotech · 2mo ago
- Chutes & Ladders—Legend CEO departs without successor in placeLegend Biotech CEO Ying Huang, Ph.D., has left the company suddenly, without a predecessor in place. Huang was elevated from CFO to CEO in 2020 after a Chinese customs investigation was opened on f…fiercebiotech · 2mo ago
- ‘Substantially better than before’: Why India has golden opportunity to build on innovative R&D winsA string of recent wins on the frontiers of novel drug development could mean that a homegrown innovation industry is within reach.fiercebiotech · 3mo ago
- Assertio accepts new buyout bid; AI biotech Isomorphic banks $2BAssertio’s latest offer represents a roughly 31% premium over an initial acquisition proposal. Elsewhere, Kyverna is readying a first-of-its-kind approval application and AC Immune is swapping CEOs.biopharma_dive · 5mo ago
comments(0)
5-min edit window · permanent after that